A61K 40/4224
Molecules with a "cd" designation not provided for elsewhere
Official title: {Molecules with a "CD" designation not provided for elsewhere}
A61K40/4224 (Molecules with a "cd" designation not provided for elsewhere) appears on 217 US grants and 697 published applications in this corpus.
Search patents in A61K- Granted patents
- 217
- Published applications
- 697
- Assignees
- 333
- Inventors
- 1,378
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 4 |
| 2003 | 0 | 0 |
| 2004 | 0 | 4 |
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 1 | 1 |
| 2008 | 0 | 2 |
| 2009 | 1 | 4 |
| 2010 | 1 | 3 |
| 2011 | 1 | 0 |
| 2012 | 3 | 4 |
| 2013 | 1 | 5 |
| 2014 | 1 | 3 |
| 2015 | 5 | 8 |
| 2016 | 3 | 14 |
| 2017 | 5 | 10 |
| 2018 | 8 | 31 |
| 2019 | 8 | 28 |
| 2020 | 19 | 40 |
| 2021 | 20 | 53 |
| 2022 | 21 | 81 |
| 2023 | 21 | 74 |
| 2024 | 26 | 131 |
| 2025 | 45 | 118 |
| 2026 | 27 | 78 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- CD5 chimeric antigen receptor for adoptive T cell therapy29 Sep 2026US 12,746,273 B2Baylor College of Medicine
- Chimeric antigen receptors (CARs) targeting hematologic malignancies, compositions and methods of use thereof15 Sep 2026US 12,735,471 B2iCell Gene Therapeutics Inc.
- Antigen-binding protein targeting CD70 and use thereof1 Sep 2026US 12,721,893 B2
- SGRNA guiding PD1 gene for cleavage to achieve efficient integration of exogenous sequences11 Aug 2026US 12,703,861 B2BRL Medicine (Shanghai) Co., Ltd.
- Compositions and Methods for Genetically Modifying CD708 Oct 2026US 2026/0308580 A1Intellia Therapeutics, Inc.
- Antibody Specifically Binding to CD276, Preparation Method Therefor and Use Thereof1 Oct 2026US 2026/0297196 A1Shanghai Sinobay Biotechnology Co., Ltd.
- Light-expressing immunoresponsive cells and uses thereof1 Oct 2026US 2026/0297517 A1Memorial Sloan Kettering Cancer Center
- Car-t cell targeting cll1, preparation method therefor and use thereof1 Oct 2026US 2026/0297519 A1Carbiogene Therapeutics Co., Ltd.
- Methods and materials for treating cancer24 Sep 2026US 2026/0284192 A1Mayo Foundation for Medical Education and Research
Most cited
By later US patents
- Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes244US 8,389,282 B2Memorial Sloan Kettering Cancer Center · 2013
- Chimeric NK receptor and methods for treating cancer159US 7,994,298 B2Trustees of Dartmouth College · 2011
- Chimeric NK receptor and methods for treating cancer128US 8,252,914 B2Trustees of Dartmouth College · 2012
- Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells83US 9,573,988 B2Novartis AG · 2017
- T cell receptor-deficient T cell compositions79US 9,181,527 B2Trustees of Dartmouth College · 2015